PMID- 28804515
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1756-283X (Print)
IS  - 1756-2848 (Electronic)
IS  - 1756-283X (Linking)
VI  - 10
IP  - 7
DP  - 2017 Jul
TI  - MMX((R)) technology and its applications in gastrointestinal diseases.
PG  - 545-552
LID - 10.1177/1756283X17709974 [doi]
AB  - The Multimatrix((R)) (MMX((R))) preparation MMX((R)) is a recently obtained drug 
      formulation developed to facilitate release of high concentrations of active 
      drugs into the colon, with a homogeneous distribution along all colonic segments, 
      particularly the most distal ones; the distal colonic tracts, indeed, are the 
      most difficult to reach in significant amounts when a drug is given orally. The 
      MMX((R)) formulation is characterized by a lipophilic matrix dispersed in a 
      hydrophilic structure. Indeed, in the last few years, MMX((R)) technology has been 
      widely used in the development of various drugs for the treatment of inflammatory 
      and infectious gastrointestinal diseases localized in the colon. In particular, 
      MMX((R)) mesalamine, budesonide and parnaparin formulations have been investigated 
      in patients with ulcerative colitis, and the first two have reached worldwide 
      registration for the treatment of this disease. Moreover, MMX((R))-rifamycin is 
      being positively tested in the treatment of colonic bacterial infections, 
      including traveler's diarrhea. MMX((R)) technology is, thus, proving to be a very 
      effective formulation for the treatment of various colonic diseases. This 
      effectiveness has been related not only to specific colonic delivery, but also to 
      its ability to act in a once-daily dosage, thus favouring patients' adherence to 
      prescribed schedules of treatment. The effective delivery of the active molecule 
      to the site of need in the colon is also associated with very low systemic 
      absorption and very low rates of adverse events (AEs). In this paper, we have 
      reviewed all clinical trials performed with an MMX((R))-bound drug and all possible 
      real-life reports, in order to give an overall evaluation of MMX((R)).
FAU - Nardelli, Silvia
AU  - Nardelli S
AD  - Department of Gastroenterology, 'Sapienza' Universita di Roma, Viale 
      dell'Universita 37, 00161, Roma, Italy.
FAU - Pisani, Laura Francesca
AU  - Pisani LF
AD  - Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Policlinico San 
      Donato, San Donato Milanese, Italy.
FAU - Tontini, Gian Eugenio
AU  - Tontini GE
AD  - Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Policlinico San 
      Donato, San Donato Milanese, Italy.
FAU - Vecchi, Maurizio
AU  - Vecchi M
AD  - Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Policlinico San 
      Donato, San Donato Milanese, Italy Department of Biomedical Sciences for Health, 
      Universita di Milano, Milan, Italy.
FAU - Pastorelli, Luca
AU  - Pastorelli L
AD  - Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Policlinico San 
      Donato, San Donato Milanese, Italy Department of Biomedical Sciences for Health, 
      Universita di Milano, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170525
PL  - England
TA  - Therap Adv Gastroenterol
JT  - Therapeutic advances in gastroenterology
JID - 101478893
PMC - PMC5484438
OTO - NOTNLM
OT  - MMX(R) technology
OT  - budesonide
OT  - mesalazine
OT  - ulcerative colitis
COIS- Conflict of interest statement: The authors declare that there is no conflict of 
      interest.
EDAT- 2017/08/15 06:00
MHDA- 2017/08/15 06:01
PMCR- 2017/07/01
CRDT- 2017/08/15 06:00
PHST- 2017/03/05 00:00 [received]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2017/08/15 06:00 [entrez]
PHST- 2017/08/15 06:00 [pubmed]
PHST- 2017/08/15 06:01 [medline]
PHST- 2017/07/01 00:00 [pmc-release]
AID - 10.1177_1756283X17709974 [pii]
AID - 10.1177/1756283X17709974 [doi]
PST - ppublish
SO  - Therap Adv Gastroenterol. 2017 Jul;10(7):545-552. doi: 10.1177/1756283X17709974. 
      Epub 2017 May 25.